Gilotrif (Afatinib Dimaleate) Patent Expiration, LOE Window & CMS Spending
Gilotrif (Afatinib Dimaleate) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2030-04-10 (last listed 2031-01-05), 2 AB generics, $66.1M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N201292 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-04-10 |
| Last Listed Patent or Exclusivity Date | 2031-01-05 |
| Orange Book Patents (*PED Extensions) | 10 patents (5 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $66.1M |
| 2024 Medicare Part D Spend | $61.1M |
| 2024 Medicaid Spend | $5.0M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 16.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.